Drug Type Small molecule drug |
Synonyms Itasetron (USAN/INN), DAU 6215, DAU-6215 + [3] |
Target |
Action antagonists |
Mechanism 5-HT3 receptor antagonists(5-hydroxytryptamine receptors, ionotropic (HTR3) antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H20N4O2 |
InChIKeyRWXRJSRJIITQAK-ZSBIGDGJSA-N |
CAS Registry123258-84-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04642 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nausea | Phase 3 | - | - | |
Nausea and vomiting | Phase 3 | United States | - | - |
Nausea and vomiting | Phase 3 | Japan | - | - |
Nausea and vomiting | Phase 3 | Europe | - | - |
Anxiety Disorders | Phase 2 | United States | - | - |
Anxiety Disorders | Phase 2 | Europe | - | - |
Cognition Disorders | Preclinical | Italy | - | - |
Psychotic Disorders | Preclinical | Italy | - | - |